Personalis Inc is primarily active in the biotechnology industry.

The main competitors of Personalis Inc in the market include companies like Illumina, Inc., Foundation Medicine, Inc., and Exact Sciences Corporation.

Personalis Inc. is a renowned genomic sequencing and data analysis company based in California. Founded in 2010, Personalis specializes in advanced technologies that enable the study of genomics at an unprecedented scale. The company combines extensive reference data with state-of-the-art analytics to provide accurate and comprehensive genomic information. Personalis has built strong capabilities in cancer genomics, aiding in the development of personalized cancer therapies. With its proprietary biotechnology platforms, Personalis offers highly accurate sequencing capabilities as well as innovative systems for analyzing genomic data. Continuously expanding its expertise and collaborations, Personalis Inc. remains at the forefront of genomic research and precision medicine.

Personalis Inc has achieved several significant milestones throughout its journey. One noteworthy achievement is the successful completion of its initial public offering (IPO) in June 2019, which marked a pivotal moment for the company. Additionally, Personalis Inc has made remarkable strides in the field of advanced genomics, providing comprehensive and accurate genomic sequencing and interpretation solutions. The company's commitment to innovation has led to various collaborations with renowned pharmaceutical and biotechnology companies, further strengthening its market position and expanding its reach. Through its consistent dedication, Personalis Inc has established itself as a leading player in the genomics industry.

Personalis Inc is primarily present in the United States and operates globally.

Personalis Inc represents a strong commitment to leveraging genomics to advance the field of precision medicine. The company focuses on providing comprehensive, accurate, and reliable genomic data to empower healthcare professionals and researchers. Personalis Inc values innovation and excellence in developing cutting-edge technologies to deliver personalized insights into an individual's genetic makeup. With an emphasis on collaboration and integrity, Personalis Inc aims to drive breakthroughs in disease research, drug development, and patient care. By harnessing the power of genomics, Personalis Inc is dedicated to improving health outcomes and transforming the future of precision medicine.

Analysts currently set an average price target of 11,22 USD for the Personalis stock (median: 11,22 USD), implying −17,0 % versus the latest price. The consensus is based on 13 analyst ratings.

Personalis Analyytikkojen kursstavoitteet 2026

13 analysts currently rate the Personalis stock: 11 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Personalis to generate revenue of 78,89 M USD and earnings per share of −0,99 USD.

Personalis Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Personalis share trades at 11,70 EUR (13,51 USD).

The Personalis share (PSNL) is listed on 4 stock exchanges, including: NASDAQ (PSNL), Frankfurt (04X.F), München (04X.MU), Düsseldorf (04X.DU).

Personalis Inc. is a company from the USA specializing in the development of personalized diagnostic and treatment solutions. The company operates in different sectors, each of which contributes uniquely to strengthening the company's life cycle. The first sector of Personalis is cancer genomics. The company has developed a platform that allows for the analysis of the genomics of cancer cells. The process involves sequencing DNA and RNA to obtain accurate information about the tumor type and its variations. With this information, Personalis develops strategies for the treatment of cancer patients and provides personalized treatment plans to its customers. Another important aspect of Personalis is genomics in immunology. Personalis utilizes its expertise to modulate the immune system of patients. The company has developed a technology that captures information about genetic variations in the immune system and uses this information to create personalized immunotherapies. This approach opens new avenues for developing treatment solutions for autoimmune diseases and other immune disorders. Personalis also has a services department that offers personalized diagnostic and treatment solutions to clinical and pharmaceutical customers. The company provides a wide range of services based on genomics, immunology, and other areas of personalized medicine. Personalis also serves the research sector through its services, equipping research laboratories in the biotechnology industry with the latest technologies to accelerate the progress of personalized medicine. The products offered by Personalis include the Cancer Genome Atlas (TCGA), a comprehensive dataset of DNA sequencing data provided to research laboratories to better understand cancer genomics and the mechanisms underlying cancer development. Personalis also offers the IMPACT test, a diagnostic platform that allows for the identification of genetic anomalies in cancer cells through sequencing. Personalis' business strategy focuses on the development of personalized diagnostic and treatment solutions, taking future advancements in medicine and biotechnology into account. Personalis aims to provide patients with the opportunity to receive the best possible treatment for their illness by leveraging the genetic information of their disease. In summary, Personalis Inc. offers innovative solutions for diagnostics and treatment through personalized medicine. With its expertise in genomics and immunology, the company covers various business fields. Personalis relies on the use of cutting-edge technologies to offer personalized solutions tailored to the specific needs of its customers. The company clearly positions itself as a leader in personalized medicine.

odotettu liikevaihto Personalis on 78,89 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Personalis on −91,32 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Personalis:n hinta-voitto-suhde (P/E) on tällä hetkellä −13,65. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Personalis-osakkeen arvostusta.

Personalis:n hinta-myynti-suhde (P/S) on tällä hetkellä 15,80. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Personalis-osakkeen arvostuskennuslukuna.

Personalis:n Eulpool-laatuscore on 2/10.

Personalis:n ISIN on US71535D1063. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Personalis:n WKN on A2PLTK. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Personalis:n ticker on PSNL. Tämä pörssinoteeraus käytetään Personalis-osakkeiden kauppaan pörssissä.

Personalis maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Personalis kuuluu sektoriin 'Terveydenhuolto'.

Personalis:n osingot jaetaan valuutassa USD.